InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $3.120 1.88 (151.61%)+
Announcement
Release
20 Feb 2025 8:41AM
Price at Release
$1.240
Full Release
download
Summary
Cogstate Ltd has released its 1H25 financial results, reporting record revenue of $23.9 million, reflecting a 19% increase compared to the previous corresponding period. The clinical trials segment saw significant growth with a revenue of $22.7 million, up 27%, despite a decline in healthcare revenue. The company executed $20.3 million in new sales contracts, marking a substantial 147% increase, and reported a total future contracted revenue backlog of $99.1 million as of December 31, 2024. Additionally, EBIT increased by 167% to $4.8 million, with a cash position of $34.2 million.
Key Points
  • Record 1H25 Revenue of $23.9M, up 19% compared to PCP
  • Clinical Trials revenue of $22.7m, up 27% compared to PCP
  • Healthcare revenue of $1.2m, down 44% compared to PCP
  • 1H25 Sales contracts executed of $20.3M, up 147% compared to PCP
  • Total future contracted revenue backlog of $99.1M at 31 December 2024
  • EBIT of $4.8M, up 167% compared to PCP
  • Cash of $34.2M at 31 December 2024
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.